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Abstract
Background. This systematic review reports on outcomes and toxicities following stereotactic radiosurgery (SRS) for non-
functioning pituitary adenomas (NFAs) and presents consensus opinions regarding appropriate patient management.
Methods. Using the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses, a 
systematic review was performed from articles of ≥10 patients with NFAs published prior to May 2018 from the 
Medline database using the key words “radiosurgery” and “pituitary” and/or “adenoma.” Weighted random effects 
models were used to calculate pooled outcome estimates.
Results. Of the 678 abstracts reviewed, 35 full-text articles were included describing the outcomes of 2671 pa-
tients treated between 1971 and 2017 with either single fraction SRS or hypofractionated stereotactic radiotherapy 
(HSRT). All studies were retrospective (level IV evidence). SRS was used in 27 studies (median dose: 15 Gy, range: 
5–35 Gy) and HSRT in 8 studies (median total dose: 21 Gy, range: 12–25 Gy, delivered in 3–5 fractions). The 5-year 
random effects local control estimate after SRS was 94% (95% CI: 93.0–96.0%) and 97.0% (95% CI: 93.0–98.0%) after 
HSRT. The 10-year local control random effects estimate after SRS was 83.0% (95% CI: 77.0–88.0%). Post-SRS hy-
popituitarism was the most common treatment-related toxicity observed, with a random effects estimate of 21.0% 
(95% CI: 15.0–27.0%), whereas visual dysfunction or other cranial nerve injuries were uncommon (range: 0–7%).
Conclusions. SRS is an effective and safe treatment for patients with NFAs. Encouraging short-term data sup-
port HSRT for select patients, and mature outcomes are needed before definitive recommendations can be made. 
Clinical practice opinions were developed on behalf of the International Stereotactic Radiosurgery Society (ISRS).
Key Points
1. SRS is an effective and safe treatment for patients with NFAs.
2. Single fraction SRS is associated with long-term (10-year) disease control for NFAs.
3. HSRT can be used in select patients with NFAs with encouraging short-term results.
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Pituitary adenomas represent 10–20% of all tumors of the 
central nervous system, of which approximately one-third 
are non-functioning.1 Multiple options exist for patients 
with newly diagnosed non-functioning adenomas (NFAs), 
including conservative management, resection, conven-
tionally fractionated external beam radiotherapy (EBRT), 
and stereotactic radiosurgery (SRS). Developments in SRS 
techniques have resulted in this becoming an alternative 
to resection for medically inoperable patients, an adju-
vant treatment for those who have undergone a subtotal 
resection, or salvage treatment for those who experience 
growth of residual disease. Multiple retrospective series 
have demonstrated favorable control rates, often >90% 
five years following SRS; however, published institutional 
series often report on cases treated over an extended 
period of time, along with either functioning pituitary 
adenomas or with other benign base-of-skull tumors.2 
Moreover, the advent of hypofractionated approaches for 
complex cases near critical structures or larger tumors 
needs further systematic evaluation.
The purpose of this systematic review of the literature 
is to describe the demographics, patient characteristics, 
treatment details, control outcomes, and treatment-related 
toxicities specifically for patients with NFAs treated with 
SRS. Based on this review, consensus opinions were made 




This systematic review of the literature was performed 
according to criteria of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA).3 Initial 
article selection was performed by searching the MEDLINE 
(PubMed) and Cochrane electronic bibliographic data-
bases, and additional primary research studies were added 
based on a review of the bibliographies of the selected ar-
ticles or other reviews of the literature. Given the reporting 
of outcomes of patients with NFAs in larger series of base-
of-skull tumors or as selected cases in generalized series of 
pituitary adenomas (including functioning tumors), these 
generic key words were used: “radiosurgery” and “pitui-
tary” and/or “adenoma.” Full text articles published in the 
English language up until May 2018 were considered and 
no publishing date restrictions were used.
The initial query identified 678 articles that were sub-
sequently screened for relevance to the objectives of the 
present report by thorough review of the article titles, ab-
stracts, and manuscripts, as necessary. Specific inclusion 
criteria included: retrospective or prospective case series 
of >10 adult patients, SRS or hypofractionated stereo-
tactic radiotherapy (HSRT; 2–5 fractions), and description 
of clinical or treatment-related toxicity outcomes specific 
to NFA patients. Exclusion criteria included: non-clinical 
reports (ie, dosimetric, physics, or basic science research 
only); expert opinion, commentary or review studies which 
did not provide unique data on >10 patients; studies on 
patients with sellar tumors of different disease entities 
(ie, craniopharyngiomas, pituitary carcinomas, and me-
tastases), pediatric-only case series, or studies which had 
fewer than 10 patients with NFAs. As some series included 
updates on prior reports from the same institution or 
multi-institutional studies with inclusion of already pub-
lished patient cohorts, duplicate studies were assessed 
for any updated data on treatment efficacy or toxicity with 
the latest report of the largest number of patients included 
in the final analysis. The search strategy used for this re-
port and the methodology for study inclusion is outlined in 
Supplementary Fig. 1.
Outcome Measures and Statistical Analysis
The primary outcomes were local control at 5 and 10 years. 
In addition, key treatment-related toxicities were evalu-
ated, such as new hypopituitarism, optic neuropathy, and 
other cranial nerve (CN) injury. R Studio v1.1.423 was used 
for statistical analyses and the R package “metafor” (v2.0-
0)4 was used for meta-analyses, tests for heterogeneity, 
analysis of publication bias, and meta-regressions. Study 
variances for overall estimate and for meta-regression 
were calculated using the DerSimonian–Laird method.5,6 
Weighted random effects models were used to calculate 
pooled estimates for 5-year local control, 10-year local 
control, and new hypopituitarism. Since the studies in-
volved patient treatment decisions, the random effects 
model was considered superior to the fixed effects model 
when calculating pooled estimates. In addition, due to the 
selected studies spanning numerous years, in a number 
Importance of the Study
SRS is commonly used for patients with non-functioning 
adenomas. However, the reports on the treatment tech-
niques and clinical outcomes, both efficacy and safety, 
are retrospective in nature, and therefore it is difficult 
to make broad conclusions by individually assessing 
studies. Therefore, on behalf of the ISRS, it was the ob-
jective of this report to provide a high-quality critical anal-
ysis of the literature to evaluate this treatment approach 
and provide key opinions for patient management. After 
an extensive review, we determined that single fraction 
SRS is associated with high control rates with long-term 
pooled outcomes, and hypofractionated approaches 
(3–5 fractions) are also associated with excellent, short-
term, outcomes. New-onset hypopituitarism is the most 
common side effect following treatment, although the 
time course for its development and clinical sequelae 
require better reporting. Cranial nerve dysfunction fol-
lowing treatment is rare.
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of different populations and in varied geographical lo-
cations, the random effects model was considered to be 
better than the fixed effects model.7,8 Nevertheless, we 
reported both estimates in the figures. The I 2 statistic was 
used for identifying heterogeneity: I 2 of 0%, 25%, 50%, and 
75% were interpreted as absent, low, moderate, and high 
heterogeneity, respectively.9 Funnel plots and the Egger 
test (P <  0.05 indicating presence of bias) were used for 
identifying publication bias. Finally, meta-regression ana-
lyses were performed to identify potential associations 
between outcomes including 5-year local control, 10-year 
local control, and new hypopituitarism as a function of 
tumor volume given the potential for bias in treatment 
fractionation selection.
Results
After a comprehensive review of the published literature, 
35 unique studies met the inclusion and exclusion criteria 
for this systematic review. All included studies were retro-
spective in nature and provided low-quality evidence. There 
was no presence of publication bias (P > 0.05) across the in-
cluded studies regarding the primary outcomes evaluated 
in this meta-analysis (Supplementary Fig. 2). A majority of 
studies (n = 31, 89%) represented single-institution reports, 
and 4 studies (11%) were multi-institutional collaborations. 
Eleven reports (31%) were published from institutions in 
the United States, whereas the majority of reports origin-
ated from institutions outside of the United States (n = 24, 
69%). The median number of patients evaluated in single 
institution reports was 31 (range: 10–272 patients).
Basic study details and patient characteristics are pre-
sented in Table 1.10–44 Across all studies, 51% of patients 
were men, and the median age was 53  years (range: 
43–69). Few patients were treated definitively with SRS 
(median 5.5%, range: 0–100%), and only 2 reports (n = 62 
and n = 69) described the outcomes of patients who were 
treated definitively due to medical inoperability or refusal 
of resection.19,20 The median value across all studies for 
the proportion of patients who had undergone resection 
prior to SRS was 95% (range: 0–100%). For these patients, 
15 studies (43%) reported the percentage of patients who 
were treated adjuvantly (immediately after resection for re-
sidual disease or within an interval without radiographic ev-
idence of disease growth) or in the salvage setting. For the 
studies reporting this distinction, the median proportion of 
patients treated adjuvantly was 47% (range: 17–96%), and 
the median proportion of patients treated in the salvage set-
ting was 53% (range: 2–83%). For most patients, SRS repre-
sented the first course of radiotherapy received; the range 
of proportions of patients who received prior radiotherapy 
was 9–17%. Given the substantial number of patients who 
had undergone resection as first-line treatment for their dis-
ease, the overall proportion of patients who had hypopitui-
tarism prior to first SRS was 45% (range: 0–83%).
Most studies reported on the tumor dimensions at the 
time of SRS, summarized in Supplementary Table 1. For 
those studies reporting tumor diameter (n =  10, 29%), 
the median dimension was 2.2  cm (range: 0.1–10.5  cm). 
For those studies reporting tumor volume (n =  30, 86%), 
the median was 3.5 cc (range: 0.03–38.7 cc). A total of 27 
studies (77%) reported on outcomes of 2451 patients 
treated with single fraction SRS to a median dose of 15 Gy 
(range: 5–25 Gy). Eight studies (23%) described the out-
comes of patients treated with HSRT, to a median dose of 
21 Gy (range: 12 Gy in 3 fractions to 25 Gy in 5 fractions). 
The radiosurgery delivery technologies included in this re-
view are CyberKnife (Accuray) (n =  6) for HSRT, Gamma 
Knife (n = 26) (Elekta) for SRS or HSRT treatments, or other 
linear accelerator–based techniques (n = 3).
The disease control and treatment-related toxicity 
outcomes are presented in Table 2. The median fol-
low-up was 42  months (range: 21–86 mo). The majority 
of studies (n = 21, 60%) reported crude, rather than actu-
arial, rates of local control ranging 90–100%. This is a pos-
sible confounder in terms of overestimating effect size. 
However, for the 10 studies reporting actuarial outcomes, 
the 5-year rate of progression-free survival (PFS) was 95% 
(range: 90–100%), identical to the studies utilizing non-
actuarial reporting methodology. Random effects meta-
analyses for 5-year local control for single fraction SRS and 
HSRT are shown in Fig. 1, with estimates of 94.0% (95% 
CI: 93.0–96.0%) and 97.0% (95% CI: 93.0–98.0%), respec-
tively. Four studies reported 10-year rates of PFS ranging 
79–100%. Fig. 2 shows the meta-analysis for 10-year local 
control after SRS with a random effects estimate of 83.0% 
(95% CI: 77.0–88.0%); HSRT outcomes were limited to 
<5 years. Reported salvage treatment included repeat SRS, 
EBRT, chemotherapy, or resection (Table 2).
Treatment-related toxicities that were evaluated in each 
of the selected articles included cerebrovascular accident 
(CVA) (n =  0), new-onset hypopituitarism (n =  31), optic 
pathway dysfunction (n = 29), other CN injury (n = 29), and 
secondary malignancy (n = 0) (Table 2). New-onset hypopi-
tuitarism ranged 0–32%. Random effects meta-analyses for 
new hypopituitarism following single fraction SRS and HSRT 
are shown in Fig. 3, with estimates of 21.0% (95% CI: 15.0–
27.0%) and 3.0% (95% CI: 1.0%–8.0%), respectively. Twenty-
four studies described dose constraints to the adjacent optic 
nerve or chiasm, with doses ranging 8–13.7 Gy in 1 fraction, 
and typically 25 Gy in 5 fractions. Declining visual function 
occurred 0–7% of the time as a result of radiotherapy, and in 
the absence of reported tumor progression. Similarly, the in-
cidence of other cranial neuropathies ranged 0–7% and were 
most often temporary in nature. CN injuries frequently in-
volved CN III, but were also seen in CNs IV, V, and VI.
Given the potential for SRS fractionation selection, 
local control, and treatment-related toxicity to be re-
lated to tumor volume, we investigated this correlation. 
Supplementary Fig. 3 shows meta-regression plots of me-
dian lesion volume versus 5- and 10-year local control and 
new hypopituitarism by SRS and HSRT. Meta-regression 
analysis did not identify a statistically significant relation-
ship for 5- and 10-year local control or new hypopituitarism 
as a function of tumor volume.
Discussion
SRS for a pituitary adenoma was first described anec-
dotally in 1968 and since then this technique has been 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































utilized for patients in the definitive setting, for residual 
disease after resection, and as salvage therapy in the set-
ting of disease recurrence.45 Several case series and insti-
tutional reports have described outcomes of patients with 
NFAs treated with SRS; however, there are clear limita-
tions to the current literature. All of the studies, single or 
multi-institutional, are effectively retrospective case series 
providing low level IV evidence. Furthermore, a broad se-
lection of patients within a case series were observed, in-
cluding those with NFAs, functioning pituitary adenomas, 
and other base-of-skull tumors. This limited a clear identi-
fication of the key patient selection criteria and treatment 
outcomes relevant for this specific analysis.
Interestingly, of the 678 published reports screened for 
this systematic review, only 35 unique studies (5.2%) were 
included after review, 20 duplicate series or prior reports 
from the same institution were identified and excluded, 
and 142 articles in the medical literature provided only a 
summary, commentary, or other type of review without re-
porting new patient data, thereby creating an anomalous 
ratio of data versus opinion of 35:142 (~1:4). The objective 
of this systematic review was to provide a summary of the 
current data regarding the role of SRS for NFA and to pro-
vide key opinions for appropriate patient management.
Treatment Efficacy
SRS was observed to be an effective treatment for pa-
tients with NFAs. The majority of patients identified in this 
review were treated in the adjuvant or recurrent setting. 
Treatment of patients definitively with SRS was often due 
to medical inoperability or patient refusal. It is important 
to note that a small proportion of patients were treated 
in the recurrent setting after prior conventional EBRT 
(0–17%), and treatment response and toxicity concerns 
may differ in this subset of patients. Although all studies 
were retrospective in nature and a minority reported actu-
arial outcomes, the pooled estimate of local control after 
5 years following single fraction SRS was favorable at 94% 
(and similar to the value of non-actuarial studies). Since 
tumor control declines with longer follow-up, it is impor-
tant to observe patients following treatment; in this meta-
analysis, the pooled local control estimate at 10 years was 
83%. Unfortunately, long-term tumor control was rarely re-
ported, with only 4 studies in this meta-analysis describing 
10-year clinical outcomes. It is important to note, however, 
that the few studies with long-term follow-up demon-
strate interesting findings on recurrence patterns. For ex-
ample, an Italian institutional series reported by Losa et al 
observed recurrences at a median of 8–9 years following 
treatment.17 After examining these late recurrences, the 
authors surmised that there are 2 different pathophysio-
logical mechanisms as well as prognostic significance to 
“in-field” and “out-of-field” late recurrences. This is es-
pecially important to identify, as practice trends are now 
changing to include the resection bed, and not only re-
sidual disease, in the treatment volume.17,25
In addition to the lack of time-dependent endpoint re-
porting, the lack of standardization of the definition of 
tumor control is clearly evident and may present a chal-































































































































































































































































































































































































































Most institutions report tumor control either as a per-
centage of tumors which reduce in size or are stable on 
imaging or with a volumetric cutoff, such as 15% or 25%, 
for tumor response and tumor progression. For a benign 
tumor, stabilization is typically the goal of treatment, but 
given that patients do experience reduction of tumor 
volume, this is also an important endpoint to describe, al-
though its clinical value could be debatable in small NFAs. 
Reduction in tumor volume may be important in terms of 
improving CN dysfunction from tumor compression or 
other neurologic symptomatology, for larger tumors. Losa 
and colleagues described different dose thresholds for 
  









































0.90 7.8% 9.5%[0.81; 0.95]
0.91 28.3% 19.0%[0.88; 0.94]
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Heterogeneity: I2 = 0%, τ2 = 0, p = 0.97





Fig. 1 Forest plot of 5-year local control following treatment of non-functioning pituitary adenomas with (A) single fraction stereotactic 
radiosurgery (SRS) and (B) hypofractionated stereotactic radiotherapy (HSRT). Squares indicate the proportions from individual studies and hor-
izontal lines indicate the 95% confidence interval. The size of the data marker corresponds to the relative weight assigned in the pooled analysis 
using the random effects model. Diamond indicates the pooled proportion with 95% CI. Both the fixed effect and random effects models pooled 
estimates are presented and heterogeneity analysis is included.
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tumor volume reduction (~17 Gy) versus tumor volume 
stabilization (~15 Gy)46; however, other reports demon-
strated similar rates of tumor volume reduction with doses 
as low as 12 Gy.25 Standardized response criteria for solid 
tumors such as the Response Evaluation Criteria in Solid 
Tumors (RECIST 1.1)47 should be included in future studies.
Dose and Fractionation Schedules
A majority of patients reported herein were treated with 
a median peripheral dose of 15 Gy. Prescription doses at 
each institution varied considerably and are typically based 



























0.7 0.8 0.90.75 0.85 0.95 1
0.79 38.6% 39.1%[0.74; 0.84]
1.00 0.4% 2.2%[0.93; 1.00]
0.85 56.0% 41.5%[0.82; 0.88]
0.83 5.0% 17.2%[0.68; 0.93]
Fig. 2 Forest plot of 10-year local control following treatment of non-functioning pituitary adenomas with single fraction SRS. Squares indicate 
the proportions from individual studies and horizontal lines indicate the 95% CI. The size of the data marker corresponds to the relative weight 
assigned in the pooled analysis using the random effects model. Diamond indicates the pooled proportion with 95% CI. Both the fixed effect and 
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0.00 14.3% 14.3%[0.00; 0.20]
0.03 85.7% 85.7%[0.01; 0.09]
0.22 6.1% 14.1%[0.12; 0.36]
0.21 61.0% 25.5%[0.18; 0.25]
0.03 1.4% 5.2%[0.00; 0.12]
0.06 1.3% 5.1%[0.01; 0.21]
0.23 15.9% 20.3%[0.16; 0.32]
0.24 5.4% 13.2%[0.12; 0.40]
0.32 8.8% 16.6%[0.20; 0.45]
A
B
Fig. 3 Forest plot of new hypopituitarism following treatment of non-functioning pituitary adenomas with (A) single fraction SRS and (B) HSRT. 
Squares indicate the proportions from individual studies and horizontal lines indicate the 95% CI. The size of the data marker corresponds to the 
relative weight assigned in the pooled analysis using the random effects model. Diamond indicates the pooled proportion with 95% CI. Both the 
fixed effect and random effects models pooled estimates are presented and heterogeneity analysis is included.
  








other words, the practice of “restriction-guided dosing.” 
The largest multi-institutional study reporting this de-
scribed 512 patients with NFAs, 94% of whom had under-
gone prior resection and 7% of whom had received prior 
EBRT; the median SRS peripheral dose of 16 Gy resulted in 
excellent tumor control rates of 95% at 5 years and 85% at 
10 years.23 However, the minimally effective dose remains 
controversial given the wide dose variation utilized in prac-
tice. Mingione and colleagues reported a minimal effec-
tive SRS dose of 12 Gy and suggested that doses greater 
than 20 Gy did not provide increased tumor control.48 
El-Shehaby and colleagues reviewed the outcomes of 21 
patients (median tumor volume 4.8 cc; 44 mo follow-up) 
treated with 12 Gy, with tumor reduction observed in 52% 
and disease stabilization in another 9 patients (43%).25 
Additional long-term studies with clear objective response 
criteria are needed to determine a potential dose threshold 
to balance the rate of tumor control with toxicities such as 
new hypopituitarism, a risk which appears to increase sig-
nificantly beyond a marginal dose of 18 Gy.20 Dose escala-
tion may be considered for patients at higher risk for local 
recurrence, such as those with larger adenomas or those 
with more aggressive subtypes, such as silent corticotroph 
staining pituitary adenomas13,49; however, firm data to 
make recommendations are lacking. Based on the avail-
able literature, we recommend a dose of 14–16 Gy for 
single fraction SRS.
Hypofractionated schedules identified in this analysis in-
cluded 21 Gy in 3 fractions,21 20 Gy in 4 fractions,15 and 
25 Gy in 5 fractions,28 with a pooled 5-year tumor control 
estimate of 97%. Each of these schedules yields a biolog-
ically equivalent single fraction dose of approximately 
11–13 Gy (assuming an α/β ratio of 3 Gy), although in vitro 
studies suggest that these may translate to a higher effec-
tive single fraction dose.50 Although the median follow-up 
periods for these reports are typically shorter than 5 years, 
the reported local control rates are high, with low rates 
of treatment-related toxicity. Given the heterogeneity in 
treatment selection, however, there was no observed dif-
ference in local control between fractionation schedules. 
Given the lack of association between tumor control and 
dose as a function of tumor volume in our meta-regression 
analyses, it is likely that dose and fractionation are most 
important for reducing the risk of toxicity, such as optic 
pathway dysfunction, rather than tumor control. Therefore, 
hypofractionated schedules can be considered for tu-
mors that are in close proximity to the optic pathways, or 
in previously irradiated situations, but limited long-term 
data prevent this from becoming a routine fractionation 
schedule. Given the lack of long-term (>10 y) tumor control 
data, patients should be consented appropriately.
Subgroups at Increased Risk for Local Recurrence
A number of factors have been evaluated for increased 
risk of tumor recurrence following SRS. Given that the arti-
cles in this meta-analysis were restricted to an SRS cohort, 
there is an initial bias in the types of tumors treated (typi-
cally well-delineated targets in the upfront or recurrent set-
ting), without inclusion of the resection cavity, and smaller 
treatment volumes. Moreover, the small sample sizes and 
relatively short follow-up of single institution reports pre-
vent detailed analysis of patient, disease, and treatment-
related factors associated with clinical outcome. Across the 
studies, the median tumor volume was 3.5 cc (effectively 
the volumetric rendition of an 18.8 mm diameter spheroid), 
and the majority of patients were treated with single frac-
tion SRS. There have been a number of variables evaluated 
for increased risk of tumor recurrence, including age, sex, 
tumor volume, presence of suprasellar extension, cav-
ernous sinus extension, timing of radiosurgery (intact vs 
postoperative and adjuvant vs salvage), and dose. When 
evaluating most SRS series individually, tumor size itself 
is not often a factor associated with treatment outcome, 
but that may be biased by the cases preselected for SRS 
as well as sample sizes (median of 31 patients per report). 
For example, in one of the largest studies with the longest 
follow-up included in this review, tumor volume was not 
associated with disease control.17 However, the median 
tumor volume in that series was only 1.5 cc (effectively the 
volumetric rendition of a 14.2 mm diameter spheroid) with 
a maximum of 2.6 cc—well below the median in this meta-
analysis. Tumor volume >5 cc (effectively the volumetric 
rendition of a 21.3 mm diameter spheroid) was an impor-
tant factor associated with disease control reported in a 
study by Narayan et al of 58 NFAs (median PFS 98.4 mo > 
5 cc compared with 136.5 mo < 5 cc, P = 0.05),11 and a sim-
ilar volume threshold of 4.5 cc (5-year PFS 86% vs 97%) by 
Park and colleagues.51 A similar finding was not observed 
in this meta-analysis as volumes and tumor control rates 
were summarized by abstracting only the medians and a 
larger patient-level study would be needed to investigate 
this further.
Upfront vs Delayed Radiosurgery
The rate of tumor recurrence after subtotal resection of 
NFAs varies widely in the literature from approximately 
20–80% by 10 years following initial resection. In this meta-
analysis, only 35% of studies reported on the proportion 
of patients treated adjuvantly versus those treated in the 
salvage setting with SRS—with half of patients treated in 
either setting. Multiple studies in the literature support 
the role of immediate fractionated EBRT compared with 
observation and salvage therapy in patients with residual 
NFAs.51,52 However, there is little consensus in the litera-
ture on the appropriate timing of SRS in patients who have 
undergone resection and have residual disease, because 
although upfront SRS might yield superior local control, it 
remains unclear whether close follow-up and salvage as 
necessary might yield similar outcomes. More recently, 
Pomeraniec et al reported on the clinical outcomes of 64 
patients (32 treated in the early setting defined as ≤6 mo 
from resection, and 32 treated in the late setting defined 
as >6 mo from resection) treated with SRS for NFAs.53 The 
authors observed a reduction in risk of radiographic and 
symptomatic progression in patients treated in the early 
group. This finding was later corroborated by a 9-center 
multi-institutional study of an expanded cohort of 222 pa-
tients, suggesting that earlier treatment results in more fa-
vorable outcomes than expectant management. Caveats 
to this management strategy include lack of clear data on 
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early salvage as described above (radiological progres-
sion) versus delayed salvage (symptomatic progression), 
as other reports stratifying patients by adjuvant treatment 
(within 6 mo) or delayed salvage (radiological progression) 
have not demonstrated benefit with early treatment.16 
Selection of patients with high risk for tumor recurrence 
after resection is complex as prediction models remain 
limited in scope at this time and further studies are clearly 
needed.
Toxicities Associated with Treatment
SRS was associated with low rates of permanent 
treatment-related toxicities. However, transient side effects 
do occur and it is important to counsel patients about these 
risks. For example, in the report by Zeiler et al, 31 of the 
76 patients (34%) in their series experienced transient side 
effects as a result of treatment; however, approximately 
75% of these toxicities were related to the stereotactic 
frame placement (including pin site swelling, infection, 
dysesthesias). Other acute toxicities included visual blur-
ring, short-term memory loss, and ataxia.22
Cranial neuropathies, injury to the carotid artery or sub-
sequent risk of CVA as a result of irradiation, and radiation 
necrosis were rarely encountered in this analysis. Narayan 
et al observed visual field deficits (n = 9, 8%), isolated CN 
palsies (n = 9, 8%), hydrocephalus (n = 3, 3%), and radia-
tion necrosis (n = 2, 2%) in a series of patients treated over 
a 17-year period without specific dosimetric or patient-
related variables associated with development of toxicity.11 
In an experience of 89 patients treated with SRS for pitui-
tary adenomas invading the cavernous sinus, Hayashi and 
colleagues reported on 2 patients who developed transient 
abducens nerve palsy and oculomotor nerve palsy; how-
ever, the latter patients received less than the prescrip-
tion dose of 24 Gy. Therefore, peritumoral edema and 
resulting compression of an adjacent nerve may also be 
a factor to consider. With the lower dosing for NFAs, cra-
nial neuropathies are rarely reported; however, in the set-
ting of cavernous sinus invasion or extrasellar extension, 
it is important to carefully delineate the adjacent cranial 
nerves to ensure they do not fall in a high-dose region.31,41 
Fractionated EBRT is associated with a 1.5- to 2-fold in-
creased risk of CVA incidence and mortality, but once 
again whether this is technique or patient/disease specific 
remains unclear.54 Fewer than 5 cases in this literature re-
ported on CVAs after SRS,55–57 of which 2 of the 3 series 
reported on patients with functioning adenomas treated 
to higher doses than NFAs. Currently no dose threshold 
exists for carotid artery stenosis, but for patients with sig-
nificant baseline risk factors and comorbidities, this should 
be considered at the time of SRS planning.
Given the smaller treatment volumes and stereotactic 
techniques, the risk is likely to be lower than that of sec-
ondary tumors following EBRT for patients with pituitary 
tumors, which was approximately 2% at 10 years and 2.4% 
at 20 years, translating to a relative risk of secondary brain 
tumor development of 10.5 compared with the incidence 
in the normal population.58 This risk is substantially lower 
in the SRS population,59 and no studies evaluated in this 
meta-analysis reported secondary cancer events.
Visual Pathway Tolerance
Optimal consideration for single fraction SRS (vs HSRT or 
EBRT) is the location of the tumor in relation to the optic 
pathways. In patients with NFAs, a dose of 10–12 Gy to 
the anterior visual pathway is usually achievable and is in 
line with the dose tolerance reported by many institutional 
series (Table 2).60 Leavitt and colleagues reported a retro-
spective review of 222 patients treated with single fraction 
SRS to benign tumors in close proximity to the visual path-
ways and reported a neuropathy risk of 9% with maximum 
doses ≤12 Gy and 10% for those >12 Gy.61 However, it is im-
portant to note the tolerance of the visual pathways in the 
setting of prior radiotherapy, as cases of vision loss in the 
re-irradiation setting have been observed.22 Nevertheless, 
cases of visual deterioration have been observed even 
with doses of less than 8 Gy.29 Although the risk for visual 
dysfunction remains low, formal visual acuity and visual 
field testing should be performed at initial diagnosis, fol-
lowing resection, and at the time of SRS to ensure accurate 
assessment of pretreatment visual function.
New Onset Hypopituitarism
The most common delayed effects of radiotherapy for 
NFAs is the risk of new onset hypopituitarism. There are 
multiple factors associated with this risk, including pa-
tient age, pituitary function prior to resection, prior sur-
gery and extent of disease resected, duration of follow-up, 
adenoma size and disease extension, and radiotherapy 
technique. This is a concern given the long natural history 
of patients with NFAs and the increased risk of death in 
those who develop secondary hypopituitarism compared 
with otherwise healthy patients.62 EBRT has been associ-
ated with a 30% risk of clinical hypopituitarism at 10 years, 
and 50% at 20 years.63 The pooled estimate of new hypo-
pituitarism was 21% following single fraction SRS in this 
meta-analysis; however, a clear time point to compare this 
could not be established. Tumor volume has been associ-
ated with hypopituitarism in some studies,29,64,65 whereas 
others have not observed this relationship,65 as was the 
finding in this study.
There are multiple factors associated with post-SRS hy-
popituitarism, including visualization of the normal pitui-
tary gland at the time of SRS target volume delineation, 
tumor extension outside of the cavernous sinus and sella, 
marginal prescription dose, and dose to the pituitary gland 
or infundibulum. Marek and colleagues reported the effect 
of marginal dose, with a 2% risk of hypopituitarism in 45 
patients treated to a mean pituitary dose <15 Gy compared 
with 73% in those with a dose >15 Gy.66 In this series, the 
dose to the distal infundibulum was also associated with 
hypopituitarism with a maximum recommended dose of 
17 Gy. Graffeo et al specifically evaluated dosimetric fac-
tors on 97 patients (57 of whom were diagnosed with 
NFAs) treated with single fraction SRS, and of the 27 pa-
tients (28%) in their series who developed posttreatment 
endocrine deficits, multivariable analysis found that male 
sex (hazard ratio [HR]: 2.38, P = 0.04), a smaller pituitary 
gland volume (HR: 0.99, P  =  0.01), and increased mean 
gland dose (HR: 1.31, P  <  0.001) were associated with 








posttreatment hypopituitarism.10 Given the various factors 
described in the literature, it is likely that the mean dose 
most closely approximates the dose received by most of 
the organ and, therefore, correlates best with long-term 
risk of hypopituitarism. On the other hand, the maximum 
dose to the infundibulum, either because of its function as 
a serial structure connecting hormonal secretion pathways 
between the hypothalamus and the pituitary or because of 
its small size, may be the most important variable to mon-
itor.67 Suprasellar extension, which has been observed in 
some series to correlate with posttreatment hypopituita-
rism,68 likely leads to higher doses to the infundibulum and 
hypothalamus, and these structures should be delineated 
and monitored at the time of SRS planning. Baseline hor-
mone levels should be obtained prior to surgery and prior 
to radiotherapy for comparison to post-SRS values.
One of the key limitations of the present review is that 
it comprises primarily retrospective cohort studies span-
ning long time intervals with limited long-term follow-up 
beyond 10 years. As patients were not treated on prospec-
tive observational study protocols, length of follow-up 
and posttreatment imaging and neuroendocrine evalu-
ation was performed at varying intervals across studies. 
This limits evaluation of key variables, especially with lack 
of time-dependent analyses. Also, every effort was made 
to prevent overlap of data across studies, and if multi-
institutional patient level data were available, these were 
given preference over individual studies as they would in-
corporate data from centers which did not always publish 
individual outcomes. However, given the multi-institutional 
nature of the data collection and analysis, fewer variables 
were reported on. Also, different multi-institutional re-
ports had overlapping time periods of data collection and 
therefore were included in order to evaluate the maximum 
number of patients, with partial but unknown quantity of 
overlap with subsequent studies.
Given the key interest of the neuro-oncology community 
in the management of patients with NFAs, as highlighted 
by the vast number of commentaries, summaries, and re-
views of the literature, it was felt timely and necessary to 
perform a meta-analysis and high-level overview of the 
role of SRS in the management of these tumors. Despite 
the aforementioned limitations of this study, key differ-
ences are important to highlight from prior works. First, 
approximately 25% of the reports included in this meta-
analysis (9/35 manuscripts) were newly published since 
the last guidelines.69 Second, this report focused on SRS, 
instead of all types of radiation therapy, and provided a 
  
Table 3 Key opinions for treatment and management of non-functioning pituitary adenomas
Recommendations for Treatment and Management of Non-Functioning Pituitary Adenomas (NFAs)
Patient Selection
1. Patients with NFAs who are medically inoperable or refuse resection can be considered for SRS as the primary definitive treatment.
2.  After resection, patients with residual disease should be presented in a multidisciplinary setting where the risks and benefits of 
immediate adjuvant SRS, or observation with salvage SRS, should be reviewed in light of patient characteristics, disease extent, pa-
thology for high-risk features, and imaging findings.
3. Prior to SRS, patients should undergo comprehensive neurological, neuro-ophthalmologic, and neuroendocrine evaluations.
4.  For patients who have received prior external beam radiotherapy, a thorough review of the prior treatment records and doses re-
ceived to nearby critical structures at risk should be evaluated by the treatment team.
Treatment
1.  A high-resolution volumetric treatment planning MRI, with at least a T1 post-gadolinium and axial T2 sequence, should be performed 
at the time of SRS to ensure accurate target volume delineation.
2.  Key at-risk structures important for consideration at the time of treatment include the hypothalamus, infundibulum, residual pitui-
tary, optic pathway, and brainstem.
3.  Single fraction SRS is preferred to HSRT if constraints to nearby structures at risk can be met given the long-term control and tox-
icity data.
a. A prescription dose of 14–16 Gy is recommended for patients treated in the definitive setting.
b. A prescription dose of 14–16 Gy is recommended for patients with residual or recurrent disease.
c.  HSRT (21 Gy in 3 fractions, 20 Gy in 4 fractions, or 25 Gy in 5 fractions) can be considered for patients with larger adenomas 
(>2–3 cm) or close to the optic apparatus; however, the lack of long-term (>10 year) tumor control data is acknowledged and pa-
tients must be consented appropriately in this context.
Treatment Outcomes
1.  Patients treated with SRS should undergo routine clinical follow-up, including neuro-ophthalmology and neuroendocrine visits, and 
imaging surveillance for at least 5 years. A schedule of every 6 months for the first year, annually for up to 5 years, and every 2 years 
thereafter is reasonable. Earlier follow-up can be considered based upon clinical events.
a. Tumor dimensions or volumetric assessments should be performed at each follow-up imaging time point using standardized re-
sponse criteria.
b.  Recurrent disease following SRS should be categorized as “in-field” or “out-of-field” recurrences and subsequent salvage treat-
ments should be comprehensively recorded in the shared medical record.
2. Treatment-related toxicities should be recorded and graded using standardized reporting criteria.
a. The development of new or worsening hypopituitarism should be defined as “biochemical” or “clinically significant.”
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more detailed analysis of key variables regarding SRS-
specific practice, study details, procedure details (dose/
fractionation), and outcome variables. For example, in this 
report, we specifically reviewed each study in great detail 
to describe key variables not addressed in prior reports, 
such as the proportions of patients treated in the definitive 
versus adjuvant versus salvage setting, incidence of prior 
radiotherapy, description of individual technique details 
(dose/fractionation), tumor volume ranges, etc, which are 
important to consider in evaluating patients for SRS and 
are different for patients receiving conventionally fraction-
ated radiotherapy. Third, the current study provides pooled 
estimates for both local control and hypopituitarism and, 
new to published literature, separated these outcomes by 
type of SRS, a specific and unique focus. Finally, this study 
analyzed SRS-specific toxicities and described them in de-
tail throughout the report. Together, these key features of 
this study make this report the most recent study on the 
role of SRS for patients with NFAs with the most updated 
data on published outcomes.
Conclusion
From this meta-analysis and detailed review of the litera-
ture for NFAs, the ISRS provides key management and key 
treatment opinions for patients with NFAs (Table 3). To re-
capitulate, SRS is an effective treatment with 10-year out-
come results for patients treated to doses of 14–16 Gy and 
promising 5-year results for radiobiologically equivalent 
HSRT schedules, with the long-term risks of new hypopitu-
itarism and rare risk of CN or vascular injury and extremely 
low risk for radiation-induced malignancy.
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